A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer (Q38373221)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer |
scientific article |
Statements
1 reference
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer (English)
1 reference
Rebecca Kristeleit
1 reference
Irina Davidenko
1 reference
Vadim Shirinkin
1 reference
Fatima El-Khouly
1 reference
Igor Bondarenko
1 reference
Michael J Goodheart
1 reference
Vera Gorbunova
1 reference
Carol A Penning
1 reference
Jack G Shi
1 reference
Xiangdong Liu
1 reference
Robert C Newton
1 reference
Yufan Zhao
1 reference
Janet Maleski
1 reference
Lance Leopold
1 reference
Russell J Schilder
1 reference
8 July 2017
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference